Thomas KellyDirector, Cell Engineering & Analytical Sciences at Johnson & Johnson Innovative MedicineSpeaker
Profile
Tom is the Director of the Cell Engineering & Analytical Sciences group for Janssen R&D, leading a team that develops the manufacturing cell lines for all secreted biologics at Janssen. He’s been a member of this team for over 20 years and has contributed to the successful approval of mAbs such as Simponi, Stelara, Tremfya, Sylvant, and Darzalex, as well as bispecific mAbs Rybrevant and Tecvayli. Prior to joining Janssen, Tom worked at the Wistar Institute in Philadelphia. He earned his degree in Chemical & Biomolecular Engineering from the University of Pennsylvania.
Agenda Sessions
Panel Discussion: Thoughts on Accelerating CLD and FIH studies
09:30View SessionWhen Will We Have a Clone? An Industry Perspective on the Typical CLD Timeline
05:00View Session